Quinnova Pharmaceuticals, Inc. Launches TERSI FOAM(TM)
Quinnova Pharmaceuticals, Inc. announced today the commercial launch of its second, water-lipid based foam prescription drug product utilizing the patented Proderm TechnologyTM. TERSI FOAM™, containing 2.25 percent selenium sulfide as its active ingredient, provides physicians and patients with the first foam, leave-on selenium sulfide therapy for the treatment of seborrheic dermatitis and tinea versicolor of the skin.
“TERSI FOAM’s cosmetically elegant, leave-on therapy and the fact that Proderm Technology helps to restore barrier function in these compromised patients will take the treatment of seborrheic dermatitis and tinea versicolor to a whole new level,” said Jeffrey S. Day, President and Chief Executive Officer of Quinnova Pharmaceuticals. “The launch of TERSI FOAM also demonstrates Quinnova’s commitment to partnering with dermatologists and their patients by offering innovative, user-friendly therapies that enhance patient compliance and treatment efficacy.”
Malassezia fungi, the underlying cause of seborrheic dermatitis, compromises patients’ natural skin barrier, which typically results in inflammation, flaking and redness of the skin. TERSI FOAM reduces the Malassezia fungi population and replenishes the physiological lipids in the skin, thereby repairing and strengthening the natural skin barrier to promote healing. Studies utilizing TERSI FOAM for the treatment of seborrheic dermatitis and tinea versicolor have demonstrated strong efficacy and patient satisfaction.
Quinnova Pharmaceuticals’ sales force calls on dermatologists across the United States.
About Quinnova Pharmaceuticals, Inc.
Quinnova Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of prescription drug products based on innovative topical drug delivery platforms. For more information, please visit www.quinnova.com.